What if a routine blood test could detect cancer years before any symptoms appeared — across multiple cancer types at once? That’s no longer a hypothesis. It’s where medicine is heading right now.
The problem with finding cancer early
Early detection is the single most powerful factor in cancer survival. Caught at stage I, many cancers have survival rates above 90%. Caught at stage IV, after metastasis has occurred, survival rates for the same cancers can drop below 20%. The challenge is that early-stage cancer is almost always silent — no symptoms, no visible mass, nothing that prompts someone to go to a doctor.
Traditional cancer detection relies on imaging (mammograms, CT scans, MRIs), physical examination, and tissue biopsies — all of which either miss early-stage disease, are too expensive or invasive to use as broad screening tools, or can only examine one area of the body at a time. Liquid biopsy technology aims to solve all of these limitations at once.
What is a liquid biopsy?
A liquid biopsy is any test that detects cancer-related material circulating in a patient’s blood — without removing tissue from the body. The primary targets are circulating tumor DNA (ctDNA): small fragments of DNA shed by cancer cells into the bloodstream, circulating tumor cells (CTCs): intact cancer cells that have broken off from a tumor and entered circulation, and extracellular vesicles (EVs): tiny membrane-enclosed particles released by cancer cells carrying molecular information about the tumor.
A study published in Frontiers in Molecular Biosciences (January 2026) by researchers from Fiocruz (Brazil) describes liquid biopsy as a paradigm shift in precision oncology — capable of not just detecting cancer, but monitoring treatment response, detecting minimal residual disease after therapy, and providing real-time information about tumor evolution and emerging resistance.
🔬 Cell-free DNA fragmentomics: Research presented at AACR 2025 demonstrated that cell-free DNA (cfDNA) fragmentome analysis can effectively identify liver cirrhosis — a major risk factor for hepatocellular carcinoma — with high accuracy, outperforming existing clinical indices. This opens the door to using liquid biopsy for cancer surveillance even before a tumor exists.
Multi-cancer early detection: one test, dozens of cancers
The most ambitious application of liquid biopsy is multi-cancer early detection (MCED) — a single blood test that can screen for multiple cancer types simultaneously. Companies like GRAIL (with their Galleri test) are already offering MCED tests commercially, designed to detect signals from over 50 cancer types in a single blood draw.
The NCI’s Vanguard Study, presented at AACR 2025, is establishing the feasibility of large-scale randomized controlled trials of MCED assays across diverse populations. Researchers also identified 19 proteins in blood associated with premenopausal breast cancer risk and 3 with postmenopausal risk — suggesting that protein biomarkers, alongside ctDNA, could become part of a comprehensive early detection panel.
AI is making liquid biopsy smarter
The signals in a liquid biopsy — fragments of tumor DNA circulating in vast amounts of normal cell-free DNA — are often extremely subtle, especially at early cancer stages. Detecting them reliably requires sophisticated computational tools. AI models are now being trained on large genomic datasets to distinguish cancer-derived signals from background noise with increasing accuracy.
According to Cancer News (Binaytara Institute, 2025), several AI models including Prov-GigaPath, Owkin’s models, and CHIEF are being applied to cancer detection from both imaging and molecular data. AlphaFold 3 is being used to predict treatment-relevant biomarkers. The combination of liquid biopsy with AI analysis is widely expected to produce the next major leap in early cancer detection.
💡 Real-world impact: If multi-cancer early detection tests prove effective at scale, they could shift cancer diagnosis from symptomatic late-stage detection to routine asymptomatic screening — the same shift that happened with mammography for breast cancer, but applied across dozens of cancer types at once.